USANA Health Sciences Q2 sales fall amid weaker Hiya and Rise performance
USNA•Outlook lowered for fiscal 2026
USANA cut its 2026 consolidated net sales outlook to $910 million from $925 million-$1.0 billion.
The company lowered its 2026 net (loss) earnings forecast to $(11) million from $20 million-$27 million.
USANA now expects 2026 adjusted diluted EPS of $0.76, down from its prior view of $1.95-$2.29.
Drivers of the quarter and key figures
- Hiya weakness - Hiya's performance was pressured by a challenging digital marketing environment, impacting topline, subscriber growth, and margins.
- Rise Wellness disruption - Rise Wellness saw a packaging-related disruption that affected commercial execution during the quarter.
- Impairment charge - The company recorded a preliminary non-cash impairment charge for Hiya, reflecting recent performance and changes in near-term forecasts.
Key details
| Metric | Beat/Miss | Actual | Consensus Estimate |
|---|---|---|---|
| Q2 Sales | Miss |
